Jason Luke, Associate Director for Clinical Research at Hillman Cancer Center, shared a post on X:
“Amazing Society for Immunotherapy of Cancer Spring Scientific on cell therapy in solid tumors!
Appreciated op to discuss IMA203. One of the hottest agents in melanoma & perhaps all of solid tumor oncology!
Very excited that the SUPRAME Ph 3 study is now accruing patients!”
